Skip to main content
SpringerLink
Log in

Amitriptyline/eletriptan/erenumab

Anxiety issues and reversible cerebral vasoconstriction syndrome: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Rozen TD, et al. Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention. Cephalalgia 42: 250-256, No. 3, Mar 2022. Available from: URL: http://doi.org/10.1177/03331024211037277

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amitriptyline/eletriptan/erenumab. Reactions Weekly 1905, 37 (2022). https://doi.org/10.1007/s40278-022-14427-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-14427-4

Search

Navigation